SI-BONE To Present at Piper Sandler 37th Annual Healthcare Conference on December 2, 2025

SI-BONE, Inc. (Nasdaq: SIBN), a leading medical device company dedicated to addressing sacropelvic disorders, has announced its participation in the Piper Sandler 37th Annual Healthcare Conference, scheduled for December 2, 2025. The event will take place in New York City, where the company's management will hold a fireside chat at 9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time. Investors can participate by registering through a designated link, with live audio streaming available on SI-BONE’s website under the "Investors" section. The webcast will be archived for at least 90 days following the conference for those unable to attend live.

Founded in 2008, SI-BONE is recognized for pioneering minimally invasive surgeries for the sacroiliac (SI) joint, particularly with its iFuse Implant System®, which has achieved widespread adoption. The company has empowered over 4,900 physicians to perform more than 135,000 procedures, supported by strong clinical evidence that includes over 180 peer-reviewed publications and four randomized controlled trials.

Beyond its flagship SI joint fusion technology, SI-BONE is advancing into adjacent markets such as adult deformity, spinopelvic fixation, and pelvic trauma, showcasing its commitment to innovation in surgical treatment. The company emphasizes its foundational goal of enhancing patient outcomes and streamlining surgical procedures, further solidifying its position as a leader in the industry.

For further information about SI-BONE, including an overview of its products and associated risks and benefits, interested parties are encouraged to visit their official website. The company continues to focus on developing groundbreaking solutions for sacropelvic disorders while fostering investor engagement through events like the upcoming healthcare conference.

As SI-BONE, Inc. (NASDAQ: SIBN) prepares to present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, investors should closely monitor the company’s developments and future outlook. SI-BONE specializes in surgical treatments for sacropelvic disorders and has a robust history of innovation, particularly with its iFuse Implant System, which has become a standard in minimally invasive SI joint surgery since its introduction in 2009.

The upcoming conference represents an excellent opportunity for the company's management to potentially share new data or insights regarding clinical advancements, product pipeline updates, or market expansions. With over 135,000 procedures supported by the company’s technology and strong clinical evidence from 180 peer-reviewed publications, investor sentiment could lean positively if management addresses strong case studies or favorable market trends during the fireside chat.

Investors should be aware of the competitive landscape as well. The medical device industry is fast-evolving, with continuous advancements in technology and surgical techniques. It will be essential to listen for SI-BONE’s strategic plans to maintain its leadership position, especially as they look to commercialize solutions in adjacent markets such as adult deformity and pelvic trauma.

Additionally, the broader healthcare market is influenced by several factors, including regulatory changes and reimbursement policies. Any insights regarding how SI-BONE intends to navigate these factors, as well as potential risks associated with their product offerings, could give investors critical context for their financial outlook.

In anticipation of the event, investors may consider keeping their positions or adding to their holdings, particularly if they believe the company can sustain its momentum within the growing market for surgical solutions. As always, investors should conduct thorough due diligence and consider market volatility when making decisions.